For example, Moderna Therapeutics has employed deep latent variable modelling combined with automated protein library design to identify ornithine transcarbamylase (OTC) variants with enhanced catalytic activity and thermal stability, thereby improving the potency of mRNA therapeutics for rare metabolic disorders [158]. The gene discussed is OTC; the disease is metabolic disease.